Three-Dimensional Quantitative Structure-Activity Relationship for Inhibition of Human Ether-a-Go-Go-Related Gene Potassium Channel
- 1 May 2002
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Journal of Pharmacology and Experimental Therapeutics
- Vol. 301 (2), 427-434
- https://doi.org/10.1124/jpet.301.2.427
Abstract
The protein product of the human ether-a-go-go gene (hERG) is a potassium channel that when inhibited by some drugs may lead to cardiac arrhythmia. Previously, a three-dimensional quantitative structure-activity relationship (3D-QSAR) pharmacophore model was constructed using Catalyst with in vitro inhibition data for antipsychotic agents. The rationale of the current study was to use a combination of in vitro and in silico technologies to further test the pharmacophore model and qualitatively predict whether molecules are likely to inhibit this potassium channel. These predictions were assessed with the experimental data using the Spearman9s rho rank correlation. The antipsychotic-based hERG inhibitor model produced a statistically significant Spearman9s rho of 0.71 for 11 molecules. In addition, 15 molecules from the literature were used as a further test set and were also well ranked by the same model with a statistically significant Spearman9s rho value of 0.76. A Catalyst General hERG pharmacophore model was generated with these literature molecules, which contained four hydrophobic features and one positive ionizable feature. Linear regression of log-transformed observed versus predicted IC50 values for this training set resulted in anr2 value of 0.90. The model based on literature data was evaluated with the in vitro data generated for the original 22 molecules (including the antipsychotics) and illustrated a significant Spearman9s rho of 0.77. Thus, the Catalyst 3D-QSAR approach provides useful qualitative predictions for test set molecules. The model based on literature data therefore provides a potentially valuable tool for discovery chemistry as future molecules may be synthesized that are less likely to inhibit hERG based on information provided by a pharmacophore for the inhibition of this potassium channel.Keywords
This publication has 23 references indexed in Scilit:
- Inhibition of HERG potassium channels by the antimalarial agent halofantrineBritish Journal of Pharmacology, 2000
- Sildenafil (Viagra) Prolongs Cardiac Repolarization by Blocking the Rapid Component of the Delayed Rectifier Potassium CurrentCirculation, 2000
- Inhibition of the human ether‐a‐go‐go‐related gene (HERG) potassium channel by cisapride: affinity for open and inactivated statesBritish Journal of Pharmacology, 1999
- Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptylineBritish Journal of Pharmacology, 1999
- Inhibition of HERG channels stably expressed in a mammalian cell line by the antianginal agent perhexiline maleateBritish Journal of Pharmacology, 1999
- The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytesBritish Journal of Pharmacology, 1997
- Which cardiac potassium channel subtype is the preferable target for suppression of ventricular arrhythmias?Pharmacology & Therapeutics, 1996
- The inward rectification mechanism of the HERG cardiac potassium channelNature, 1996
- A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channelCell, 1995
- A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndromeCell, 1995